(Q40256798)

18 September 2017

Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts (English)

1 reference

18 September 2017

1 reference

1 reference

1 reference

Yoshifumi Takei

1

1 reference

18 September 2017

Kenji Kadomatsu

series ordinal

2

1 reference

18 September 2017

Tatsunori Goto

series ordinal

3

1 reference

18 September 2017

Takashi Muramatsu

series ordinal

4

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

18 September 2017

1 reference

18 September 2017

107

1 reference

18 September 2017

4

1 reference

18 September 2017

864-873

1 reference

Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis

18 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

siRNA therapeutics: big potential from small RNAs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Midkine and pleiotrophin in neural development and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Morpholino antisense oligomer targeting human midkine: its application for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Immunohistochemical analysis of midkine expression in human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22068

7 January 2021

Identifiers

DOI

10.1002/CNCR.22068

1 reference

18 September 2017

1 reference